SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R‐CHOP) is widely accepted as standard care for diffuse large B‐cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R‐IPI) was established in 2007 after the addition of rituxi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Sci
Hoofdauteurs: Tomita, Naoto, Sakai, Rika, Fujisawa, Shin, Fujimaki, Katsumichi, Taguchi, Jun, Hashimoto, Chizuko, Ogawa, Koji, Yamazaki, Etsuko, Ishigatsubo, Yoshiaki
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2012
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659199/
https://ncbi.nlm.nih.gov/pubmed/22587388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02331.x
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items